No abstract

Background: Disease-modifying antirheumatic drugs (DMARDs) have been suggested in the treatment of inflammatory ophthalmological diseases. The aim of the present study was to investigate the effects of these DMARDs on bovine retinal function. Methods: Bovine retina preparations were perfused with a standard solution. After recording stable electroretinograms the nutrient solution was substituted by a DMARD medium with varying concentrations of different drugs (etanercept and infliximab) for 30 min. Afterwards b-wave recovery was observed. Results: Significant decreases in the b-wave amplitude (p < 0.05) were found for etanercept 0.5 mg/ml (p = 0.0022). Infliximab 2 mg/ml (p = 0.1276) did not result in any statistically significant b-wave reduction. Conclusion: The presented data suggest that infliximab might have the better safety profile than etanercept.

PurposeBlockage of the interleukin 1 (IL-1) signaling pathway has been proposed for treatment of inflammatory disorders like those affecting the retina and its adjacent tissue. Herein, we evaluated one of those inhibitory drugs, anakinra (Kineret®), based on its safety profile with emphasis on retinal function from an electrophysiological point of view.MethodsBovine retina preparations were perfused with two different concentrations of anakinra (1 mg/ml and 2 mg/ml). An electroretinogram (ERG) was recorded and b-wave recovery assessed.ResultsExposure to anakinra at a concentration of 1 mg/ml did not decrease the b-wave amplitude, whereas 2 mg/ml resulted in a significant reduction.ConclusionsBased on these preliminary results, anakinra at a dose as low as 1 mg/ml could be regarded as safe for retinal function. However, dosages of 2 mg/ml and more do have toxic electrophysiological effects, at least for the short-term.